ERASErasca, Inc.Finished
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Metastatic Colorectal Cancer · Metastatic Pancreatic Ductal Adenocarcinoma
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Aug 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 1/2
- Patients
- 101 (final count)
- Started
- Sep 20, 2021
- Main results expected
- Aug 15, 2025
- Fully finished
- Jan 26, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Limiting Toxicities (DLT)
Measured over: Study Day 1 up to Day 29
Maximum Tolerated Dose (MTD)
Measured over: Study Day 1 up to Day 29
Recommended Dose (RD)
Measured over: Study Day 1 up to Day 29
Adverse Events
Measured over: Assessed up to 24 months from time of first dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-08-15, no fading
Raw record changes
- none yet
Trial ID NCT05039177 · record last updated 2026-03-25 · checked 2026-11-09 15:36 UTC